In conclusion, we provide evidence that the BRCA1 p.Ser36Tyr variant abrogates BRCA1 protein function and based on clinical, epidemiological, genetic and functional assay data we suggest that this variant is associated with a moderate risk of breast and ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.